The biomanufacturing of retroviral and lentiviral vectors

由于现有包装细胞系的粘附性，用于大规模临床试验的逆转录病毒载体的生产受到限制。此外，用于补充培养液的血清可能会导致蛋白质、病毒和普恩等生物污染物的引入。血清也是一种昂贵的原材料，它增加了下游处理(纯化、浓缩和传染性病毒回收)的复杂性、持续时间和成本。我们正在计划培养逆转录病毒和慢病毒包装细胞系，这些细胞系可以在悬浮和无血清培养基(SFM)中生长。具有这种特性的细胞可以在生物反应器中生物制造载体，几乎没有大小限制。

The production of retroviral vectors for large-scale clinical trials is limited due to the adherent nature of the existing packaging cell lines. Furthermore, serum used to supplement media can contribute to introduce biological contaminants like proteins, viruses and prions. Serum is also an expensive raw material and it increases the complexity, duration and cost of downstream processing (purification, concentration and infectious virus recovery). We are proposing to generate retroviral but also lentiviral packaging cell lines that could grow in suspension and serum-free media (SFM). Cells with such properties could allow the biomanufacturing of vectors in bioreactors with practically no size limit.